The Utility of Thromboelastography for Guiding Recombinant Activated Factor VII Therapy for Refractory Hemorrhage After Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 23, Issue 6, 2009, Pages 828-834

  Wasowicz, Marcin ^a,b   Meineri, Massimiliano ^a,b   McCluskey, Stuart M ^a,b   Mitsakakis, Nicholas ^a,b   Karkouti, Keyvan ^a,b,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

cardiac surgery; recombinant factor VIIa; thromboelastography

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HEART SURGERY; HUMAN; MALE; MEDICAL RECORD; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; CARDIAC SURGICAL PROCEDURES; COAGULANTS; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70450225076     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2009.03.012     Document Type: Article

References (25)

1. Karkouti K., Wijeysundera D.N., Yau T.M., et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 44 (2004) 1453-1462
2. Von Heymann C., Redlich U., Jain U., et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery-A retrospective analysis of safety and efficacy. Crit Care Med 33 (2005) 2241-2246
3. Hyllner M., Houltz E., and Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 28 (2005) 254-258
4. Karkouti K., Beattie W.S., Wijeysundera D.N., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: A propensity score-matched case control analysis. Transfusion 45 (2005) 26-34
5. Karkouti K., Beattie W.S., Crowther M.A., et al. The role of recombinant factor VIIa in on-pump cardiac surgery: Proceedings of the Canadian Consensus Conference. Can J Anesth 54 (2007) 573-582
6. O'Connell K.A., Wood J.J., Wise R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
7. Karkouti K., Beattie W.S., Arellano R., et al. A comprehensive Canadian review of the off-label use of recombinant activated Factor VII in cardiac surgery. Circulation 118 (2008) 331-338
8. Hall K., Forrest P., and Sawyer C. The effects of acidosis and hypothermia on blood transfusion requirements following factor VII administration. Anaesth Intensive Care 35 (2007) 494-497
9. Stein D.M., Dutton R.P., O'Connor J., et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma 59 (2005) 609-615
10. Mayo A., Misgav M., Kluger Y., et al. Recombinant activated factor VII (NovoSeven) addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 87 (2004) 34-40
11. Bowles K.M., Callaghan C.J., Taylor A.L., et al. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage. Br J Anaesth 97 (2006) 476-481
12. Martinowitz U., and Michaelson M. Guidelines for the use of recombinant activated factor VII(rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rVIIa Task Force. J Thromb Haemost 3 (2005) 640-648
13. Key N.S., and Nelsestuen G.L. Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol 41 suppl 1 (2004) 51-54
14. Young G., Blain R., Nakagawa P., et al. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 12 (2006) 598-604
15. Sørensen B., and Ingerslev J. Thromboelastography and recombinant factor VIIa- hemophilia and beyond. Sem Hematol 41 suppl 1 (2004) 140-144
16. Sørensen B., and Ingerslev J. Tailoring haemostatic treatment to patient requirements: An update on monitoring haemostatic response using trombelastography. Haemophilia 11 suppl 1 (2005) 1-6
17. Pivalizza E.G., and Escobar M.A. Thromboelastography-guided factor VIIa therapy in a surgical patients with severe hemophilia and factor VIII inhibitor. Anesth Analg 107 (2008) 398-401
18. Trowbridge C.C., Stammers A.H., Ciccarelli N., et al. Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and higher titer inhibitors to factor VII: A case report and brief review. J Extra Corpor Technol 38 (2006) 254-259
19. Wa{ogonek}sowicz M., Srinivas C., Meineri M., et al. Technical report: Analysis of citrated blood with thromboelastography: comparison with fresh blood samples. Can J Anesth 55 (2008) 284-289
20. Camenzind V., Bombeli T., Seifert B., et al. Citrate storage affects thromboelastography analysis. Anesthesiology 92 (2000) 1242-1249
21. Despotis G., Eby C., and Lublin D.M. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 48 (2008) 2S-30S
22. Paparella D., Brister S.J., and Buchanan M. Coagulation disorders of cardiopulmonary bypass: A review. Intensive Care Med 30 (2004) 1873-1881
23. Avidan M.S., Da Fonseca J., Parmar K., et al. The effects of aprotinin on thromboelastography with three different activators. Anesthesiology 95 (2001) 1169-1174
24. Ranuci M., Isgro G., Soro G., et al. Efficacy and safety of recombinant activated factor VII in major surgical procedures. Systematic review and meta-analysis of randomized clinical trials. Arch Surg 143 (2008) 296-304
25. Johnson S.J., Ross M.B., and Moores K.G. Dosing Factor VIIa (recombinant) in non-hemophiliac patients with bleeding after cardiac surgery. Am J Health Syst Pharm 64 (2007) 1808-1812